Change in Brain Plasmalogen Composition by Exposure to Prenatal Undernutrition Leads to Behavioral Impairment of Rats.
hyperactivity
maternal undernutrition
plasmalogen phosphatidylethanolamine
prefrontal cortex
Journal
The Journal of neuroscience : the official journal of the Society for Neuroscience
ISSN: 1529-2401
Titre abrégé: J Neurosci
Pays: United States
ID NLM: 8102140
Informations de publication
Date de publication:
25 09 2019
25 09 2019
Historique:
received:
21
10
2018
revised:
28
07
2019
accepted:
31
07
2019
pubmed:
9
8
2019
medline:
7
7
2020
entrez:
9
8
2019
Statut:
ppublish
Résumé
Epidemiological studies suggest that poor nutrition during pregnancy influences offspring predisposition to experience developmental and psychiatric disorders. Animal studies have shown that maternal undernutrition leads to behavioral impairment, which is linked to alterations in monoaminergic systems and inflammation in the brain. In this study, we focused on the ethanolamine plasmalogen of the brain as a possible contributor to behavioral disturbances observed in offspring exposed to maternal undernutrition. Maternal food or protein restriction between gestational day (GD) 5.5 and GD 10.5 resulted in hyperactivity of rat male adult offspring. Genes related to the phospholipid biosynthesis were found to be activated in the PFC, but not in the NAcc or striatum, in the offspring exposed to prenatal undernutrition. Corresponding to these gene activations, increased ethanolamine plasmalogen (18:0p-22:6) was observed in the PFC using mass spectrometry imaging. A high number of crossings and the long time spent in the center area were observed in the offspring exposed to prenatal undernutrition and were mimicked in adult rats via the intravenous injection of ethanolamine plasmalogen (18:0p-22:6) incorporated into the liposome. Additionally, plasmalogen (18:0p-22:6) increased only in the PFC, and not in the NAcc or striatum. These results suggest that brain plasmalogen is one of the key molecules to control behavior, and its injection using liposome is a potential therapeutic approach for cognitive impairment.
Identifiants
pubmed: 31391260
pii: JNEUROSCI.2721-18.2019
doi: 10.1523/JNEUROSCI.2721-18.2019
pmc: PMC6764206
doi:
Substances chimiques
Plasmalogens
0
phosphatidal ethanolamines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7689-7702Informations de copyright
Copyright © 2019 the authors.
Références
J Neurochem. 2001 May;77(4):1168-80
pubmed: 11359882
Mol Cell Endocrinol. 2001 Dec 20;185(1-2):93-8
pubmed: 11738798
Arch Gen Psychiatry. 2003 Jun;60(6):565-71
pubmed: 12796219
Neuroscience. 2004;129(4):971-81
pubmed: 15561412
Nat Rev Mol Cell Biol. 2005 Oct;6(10):777-88
pubmed: 16314867
Biol Psychiatry. 2006 Sep 15;60(6):554-62
pubmed: 16997000
J Autism Dev Disord. 2008 Mar;38(3):481-8
pubmed: 17619130
Nat Rev Neurosci. 2008 Feb;9(2):110-22
pubmed: 18209730
Arch Gen Psychiatry. 2008 Feb;65(2):146-52
pubmed: 18250252
Schizophr Bull. 2008 Nov;34(6):1054-63
pubmed: 18682377
Biochim Biophys Acta. 2008 Nov;1778(11):2594-603
pubmed: 18789885
FASEB J. 2010 Jun;24(6):2104-15
pubmed: 20124437
Endocrinology. 2010 Apr;151(4):1622-32
pubmed: 20176722
J Chromatogr A. 2010 Jun 18;1217(25):4229-39
pubmed: 20452604
Psychopharmacology (Berl). 2011 Mar;214(1):89-106
pubmed: 20949351
J Neurochem. 2011 Mar;116(5):916-25
pubmed: 21214572
J Biosci Bioeng. 2011 Sep;112(3):292-8
pubmed: 21641865
Neuropsychopharmacology. 2012 Mar;37(4):929-38
pubmed: 22089319
Neuropharmacology. 2013 May;68:184-94
pubmed: 22564440
Biochim Biophys Acta. 2012 Sep;1822(9):1442-52
pubmed: 22627108
PLoS One. 2012;7(7):e40459
pubmed: 22792336
Brain Behav Immun. 2013 Feb;28:196-206
pubmed: 23207108
Neuron. 2013 Jan 23;77(2):259-73
pubmed: 23352163
JAMA Psychiatry. 2013 Jan;70(1):49-58
pubmed: 23404112
Curr Opin Neurol. 2013 Apr;26(2):146-53
pubmed: 23406909
Psychopharmacology (Berl). 2013 Jul;228(1):19-30
pubmed: 23407782
Neuroscience. 2013 Jun 14;240:1-12
pubmed: 23454542
J Hum Nutr Diet. 2014 Apr;27 Suppl 2:284-91
pubmed: 23495677
J Lipid Res. 2014 Mar;55(3):504-15
pubmed: 24367044
Nature. 2014 May 22;509(7501):503-6
pubmed: 24828044
Traffic. 2015 Jan;16(1):1-18
pubmed: 25243850
J Child Psychol Psychiatry. 2015 Jun;56(6):632-9
pubmed: 25283790
Neuroscience. 2015 Feb 12;286:79-86
pubmed: 25446346
Brain Res. 2015 Aug 18;1617:28-46
pubmed: 25451133
Biochim Biophys Acta. 2015 Feb;1851(2):117-28
pubmed: 25463479
Biol Psychiatry. 2015 Jun 1;77(11):940-50
pubmed: 25499957
Nutrition. 2015 Jun;31(6):781-6
pubmed: 25933483
Anal Bioanal Chem. 2015 Jul;407(18):5273-80
pubmed: 25957845
Anal Chem. 2015 Nov 17;87(22):11176-81
pubmed: 26492538
Biochim Biophys Acta. 2016 May;1863(5):934-55
pubmed: 26686055
Psychiatry Res. 2016 Feb 28;236:91-97
pubmed: 26753951
Pharmacol Rev. 2016 Jul;68(3):816-71
pubmed: 27363441
Neuropsychopharmacology. 2017 Jan;42(2):572-580
pubmed: 27681441
Biomed Res Int. 2016;2016:3821579
pubmed: 27689077
Int J Nanomedicine. 2016 Oct 18;11:5381-5414
pubmed: 27799765
Curr Opin Lipidol. 2017 Feb;28(1):60-67
pubmed: 27922847
Transl Psychiatry. 2017 Jan 31;7(1):e1015
pubmed: 28140405
J Neurosci. 2017 Apr 12;37(15):4074-4092
pubmed: 28292831
Genes (Basel). 2017 Mar 18;8(3):
pubmed: 28335457
Exp Neurol. 2018 Jan;299(Pt A):228-240
pubmed: 28455196
Protein Cell. 2018 Feb;9(2):196-206
pubmed: 28523433
FEBS Lett. 2017 Sep;591(18):2720-2729
pubmed: 28686302
Eur Child Adolesc Psychiatry. 2018 Feb;27(2):139-148
pubmed: 28712019
J Psychiatr Res. 2017 Dec;95:135-142
pubmed: 28843843
Gen Comp Endocrinol. 2018 May 1;260:58-66
pubmed: 29277418
Congenit Anom (Kyoto). 2019 Mar 18;:null
pubmed: 30883939
J Neurochem. 1976 Feb;26(2):377-85
pubmed: 3631
J Mol Biol. 1982 Jun 5;157(4):635-58
pubmed: 6214639
Brain Res. 1997 Oct 24;772(1-2):181-90
pubmed: 9406971
Soc Psychiatry Psychiatr Epidemiol. 1998 Aug;33(8):373-9
pubmed: 9708024
Physiol Behav. 1998 Jun 1;64(3):373-80
pubmed: 9748107